 |
|
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Karim Seif El Dahan, Darine Daher, Amit G. Singal
Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online 2022 Sep 14 DOI: https://doi.org/10.3350/cmh.2022.0247
|
|
Citations to this article as recorded by
 Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608. CrossRef Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 355. CrossRef Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas
Diagnostics.2023; 13(16): 2631. CrossRef
|